Fmr LLC Sells 4,323,879 Shares of Alkermes Plc (NASDAQ:ALKS)

FMR LLC lowered its holdings in shares of Alkermes Plc (NASDAQ:ALKS) by 27.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,649,172 shares of the company’s stock after selling 4,323,879 shares during the period. FMR LLC owned about 7.42% of Alkermes worth $425,079,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Pendal Group Ltd purchased a new stake in Alkermes during the first quarter worth approximately $82,000. Globeflex Capital L P acquired a new stake in Alkermes in the first quarter valued at $148,000. Commerce Bank acquired a new stake in Alkermes in the first quarter valued at $201,000. NumerixS Investment Technologies Inc raised its holdings in shares of Alkermes by 756.9% during the fourth quarter. NumerixS Investment Technologies Inc now owns 7,712 shares of the company’s stock worth $220,000 after purchasing an additional 6,812 shares during the period. Finally, Westpac Banking Corp acquired a new stake in shares of Alkermes during the fourth quarter worth $273,000. 97.38% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on ALKS shares. Citigroup increased their target price on shares of Martin Marietta Materials from $239.00 to $255.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. TheStreet cut shares of Trinseo from a “b-” rating to a “c+” rating in a report on Friday, May 17th. Zacks Investment Research cut shares of Wix.Com from a “hold” rating to a “sell” rating in a report on Monday, April 8th. JPMorgan Chase & Co. cut shares of Engie to a “hold” rating in a report on Wednesday, April 10th. Finally, HC Wainwright set a $25.00 target price on shares of Epizyme and gave the company a “buy” rating in a research report on Friday, May 31st. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $37.45.

In related news, Director Richard F. Pops sold 110,000 shares of Alkermes stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $24.88, for a total value of $2,736,800.00. Following the completion of the transaction, the director now directly owns 776,433 shares of the company’s stock, valued at $19,317,653.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Landine sold 20,000 shares of Alkermes stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.93, for a total value of $498,600.00. Following the completion of the transaction, the senior vice president now directly owns 193,426 shares of the company’s stock, valued at $4,822,110.18. The disclosure for this sale can be found here. Insiders have sold 195,373 shares of company stock worth $4,905,080 in the last quarter. Corporate insiders own 4.71% of the company’s stock.

ALKS stock traded down $0.41 during midday trading on Friday, hitting $22.53. 941,669 shares of the company traded hands, compared to its average volume of 1,431,579. Alkermes Plc has a twelve month low of $21.29 and a twelve month high of $46.98. The company has a quick ratio of 2.65, a current ratio of 2.94 and a debt-to-equity ratio of 0.25. The firm’s 50 day simple moving average is $22.60. The company has a market cap of $3.60 billion, a PE ratio of -321.86 and a beta of 1.83.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, April 25th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.06. The business had revenue of $223.10 million for the quarter, compared to the consensus estimate of $218.84 million. Alkermes had a negative net margin of 15.86% and a negative return on equity of 2.08%. Alkermes’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the company posted ($0.09) earnings per share. Research analysts anticipate that Alkermes Plc will post -0.34 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Recommended Story: How is diluted EPS different from basic EPS?

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.